



Transforming Patient-Centric Heart Care

Delivering specialized ECG-based AI digital health solutions customized to provide our clinical research and commercial pharmaceutical partners with patient's heart rhythm data—anytime, anywhere.

SOLUTIONS THAT GROW WITH YOU

CLINICAL RESEARCH

Supports traditional and decentralized clinical trials

Screening for at-risk patients

COMMERCIAL

On-going cardiac safety monitoring

Customized programming

(Drugs+ and Beyond the Pill)

Removes barriers and enables compliance with treatments requiring cardiac monitoring

THE ALIVECOR ADVANTAGE



World's only FDA-cleared medical-grade 6-lead personal ECG device; shown to have higher accuracy than single-lead smartwatches¹



Record ECGs with InstantQT measurements in only 30 seconds at home or in-office, reducing costs and travel time²



Seamless integration into leading EHR platforms



Easy to read AI determinations for non-cardiologists with option for cardiology overread program



EASE & SIMPLICITY FOR ALL STAKEHOLDERS



KardiaMobile® 6L

Medical-grade
6-lead ECGs
(for ages 18+)



KardiaStation™

App designed
for in-office
ECGs screening
for at-risk patients



KardiaRx™

Customizable IOS/
Android app designed
for use in clinical trials
or remote monitoring



KardiaPro®

HIPPA-compliant,
SOC-2 certified
web-based
clinician portal

THREE SIMPLE STEPS



Step 1

6-lead ECG recorded in
30 seconds by professional
or non-professional*

*QT interval reading only available if ECG
taken by professional under prescription



Step 2

App immediately provides
the results, including rhythm
determination and automated
QT interval measurements¹



Step 3

Data securely stored, fitting into
practice workflow through KardiaPro
web-based portal or integration
options with EHR, SDK, or API

Speak with us today to develop
customized solutions and explore
partnership opportunities

Contact us:
biopharma@alivecor.com

Learn more:
kardia.com/biopharma



1. Scholten J, et al. Six-lead device superior to single-lead smartwatch ECG in atrial fibrillation detection. American Heart Journal (2022), doi: <https://doi.org/10.1016/j.ahj.2022.06.010>
2. FDA-cleared to provide QT, QTcf, and QTcb measurements. KardiaMobile 6L does not check for myocardial infarction (heart attack)

189 Bernardo Avenue, Mountain View, CA 94043

Registered trademarks of AliveCor, Inc. | © 2022 AliveCor, Inc. All Rights Reserved. | MKT-0167.1